Compare SLRC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | PHAR |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.0M | 917.4M |
| IPO Year | 2007 | 2020 |
| Metric | SLRC | PHAR |
|---|---|---|
| Price | $13.34 | $13.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $15.14 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 558.8K | 14.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.09 | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $42.05 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.83 | $9.54 |
| 52 Week High | $17.20 | $21.34 |
| Indicator | SLRC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 38.40 |
| Support Level | $12.83 | $11.84 |
| Resistance Level | $15.65 | $13.44 |
| Average True Range (ATR) | 0.24 | 0.42 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 88.03 | 52.85 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.